|
|
 |
|
Viewing report
|
|
|
|
Overview of Indian Oncology Market
Frost & Sullivan, Dec 2009, Pages: 169
This Frost & Sullivan research service titled Overview of Indian Oncology Market provides an understanding of various cancer indications and their market structure. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: breast cancer, lung cancer market, prostate cancer market, head and neck cancer market, ovarian cancer market, cervical cancer market, renal cell carcinoma market and pancreatic cancer market.
Market Overview
Expanding Ageing Population and Better Outreach of Modern Therapies Fuels Growth in the Indian Oncology Market
The Indian oncology market is witnessing strong growth alongside fast-paced development in the pharmaceutical sector. The market is expected to grow at a compound annual growth rate (CAGR) of 21 percent from 2008 to 2014, driven by the introduction of new treatments, increasing number of patients on chemotherapy, and improved access to modern cancer therapies. Cancer is one of the ten leading causes of death in India. Nearly half the cases are curable if detected early. Due to the high prevalence of cancer, the oncology market is witnessing fast-paced growth. High spending on therapeutic drugs for cancer in the emerging economies including India is fuelling market growth. 'With the expanding base of patients undergoing chemotherapy in the major markets and greater access to modern therapies, cancer drugs are poised for widespread uptake,' notes the analyst of this research service. 'Moreover, the increase in the ageing population is another factor contributing positive momentum for the market.' A 40 to 50 percent increase in incidences can be seen for some of the major cancer indications such a prostate cancer, breast cancer, ovarian cancer, head and neck cancer. Also the high prevalence of smoking is loading to the proliferation in the number of patients afflicted with lung cancer.
Trends indicate that the incidence of cancer will is set to assume dangerous proportions in the future, making the disease one of the major chronic diseases that will continue to impact people’s lives. Going forward, greater progress in cancer therapy is envisioned along with more light being thrown on the cause of the disease. Yet, it remains to be seen how much the refinement in the present detection, diagnostic, and therapeutic technologies will help in containing the spread of the disease. Large quantities of generic drugs are available in the market for cancer treatment. Chemotherapy is highly genericised. These products are low-priced and hence place restrictions on potential revenues.
In this market with increasing competition and generic players, it is important to strategically position products as early in their life cycle as possible to generate the most revenue prior to patent expiration. For the competitive chemotherapy market, showing superior efficacy and less toxicity in combination with targeted therapy drugs is one of the best ways to distinguish the product over others. 'To be successful in the cancer market of the future, it is imperative for product to be established as an integral part of the standard combination therapy regimen,' says the analyst. 'This will guarantee strong revenue and the most value to patients.' Identifying optimal drug combinations, which significantly increase median survival, tumor resolution and reduce toxicity and adverse effects should be the prime task for companies in the cancer therapeutic market.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Pharmaceuticals
- Biotechnology
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Oncology Market in India to 2017 - Limited Patient Affordability for High Priced Biologics Lowers Market Potential
Global Prostate Cancer Therapeutics Market (2010 – 2020) (Opportunity Analysis, Pipeline Assessment & Market Forecast)
European Market for Interventional Oncology Technology
Clinical Trial Recruitment Strategies in Oncology - Online Recruitment Methods and Use of IT - enabled Patient Management Systems will Reduce Recruitment Time and Cost
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
Oncology Therapeutics Market to 2017 - High Unmet Need in the Management and Treatment of Metastatic Cancers to Drive Drug Development
Non-small Cell Lung Cancer Drug Market in South Korea
Oncology Market in China to 2017 - Better Access to Cancer Therapies for the Rising Cancer Population through Healthcare Reforms Drives the Market
Global Cancer Biomarkers Market (2010 - 2015)
|
|
|
|
